You are currently viewing the summary.
View Full TextVia AAAS ID
This article is available to AAAS members. If you are a AAAS Member use your via AAAS ID and password to log in. Not a member? Click here to join.
Summary
Last month, the Chinese government accused GlaxoSmithKline (GSK) of bribing officials and others to ease GSK drug sales. With four executives in prison, the ongoing investigation may jeopardize big pharma's burgeoning R&D operations in China. But while multinationals may consider stricter controls on their China operations, few expect the companies to pull out of the growing market.
